AlphAIAlphAI — Financial news for AI agents
investing.com$CDNA

Caredx Inc earnings beat by $0.44, revenue topped estimates

Caredx Inc (CDNA) reported Q3 EPS of $0.70, beating estimates by $0.44, with revenue of $139M, exceeding expectations. The company forecasted FY 2026 revenue of $520M-$530M, higher than analyst consensus. CDNA's stock is up 63.62% over the last 3 months and 393.37% over the last year.

Original reporting
investing.com
Published Oct 29, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CDNA
Bullish
high confidence
Mentioned
$CDNA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CDNABullishHigh
01

Why it matters

Earnings beat and raised FY2026 revenue guidance provide a fresh catalyst for the stock.

02

Market read

The earnings surprise offers a short‑term trading opportunity for CDNA.

03

What to watch

Potential dilution from upcoming financing not discussed.

Relevance 7/10Novelty 8/10Timing: after-hours reaction

Background

Caredx Inc (NASDAQ: CDNA) is a health‑technology company reporting its Q3 results.

Company-level read

Ticker impact

$CDNABullishHigh confidence
Context

Caredx Inc reported Q3 EPS of $0.70 beating estimates by $0.44 and revenue of $139M above consensus.

Expected impact

likely upward pressure as market prices in the earnings beat and higher guidance

Evidence & confidence

The surprise EPS beat and upward revenue guidance are fresh primary disclosures that can drive short-term buying.

Market effects

Sector

Positive earnings may lift other health‑tech peers.

Regional

Limited to US‑listed biotech sector.

Global

Low global impact.

Counterpoint

What could challenge this read

If guidance falls short of expectations later, the rally could reverse.

Key entities

  • Company
    Caredx Inc

    Health‑tech firm reporting earnings.

Read at source← All news

StoryCareDx posts Q3 2026 earnings, lifts full‑year revenue outlook to $520‑$530 million

Also covered by

5 outlets

Related articles

$CDNALow

Why CareDx Stock Soared Today

CareDx (CDNA) shares rose 22% after Q3 revenue surged 39% YoY to $139M, driven by 65% growth in testing services. Testing volumes increased 51% to 75,900, aided by the Naveris acquisition. EBITDA doubled to $30M. The company raised full-year revenue guidance to $525M and adjusted EBITDA targets to $90M-$100M, citing growing interest in precision medicine diagnostics.

finance.yahoo.com
$CDNAHighAI 8/10

CareDx Soars 20% on Big Q3 Beat and Guidance Raise

CareDx's shares rose 20% after Q3 revenue increased 39% to $139M, surpassing expectations. The company raised 2026 revenue guidance to $520M-$530M. Adjusted EBITDA doubled to $30M. Natera, a competitor, reports next week, which may indicate market growth or share shifts.

finance.yahoo.com